MODAG starts first-in-human Phase 1 clinical trial for Anle138b
Category: #health  By Pankaj Singh  Date: 2019-12-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

MODAG starts first-in-human Phase 1 clinical trial for Anle138b

MODAG has announced the start of clinical trial and recruitment for a first-in-human Phase 1 study of Anle 138b in healthy volunteers. Reportedly, the compound is being fostered for the Multiple System Atrophy (MSA)’s treatment with the capability to be used in other synucleinopathies, including Parkinson’s disease. Embellishing the Company’s patent estate for anle138b to exclusive global coverage, MODAG not long ago secured a US patent for anle138b.

MODAG’s CEO Dr. Torsten Matthias was reportedly sanguine of the trial and said the company is on course to conduct the tests that will bring anle138b a step closer to patients. Shedding light on the relevance of attaining global patent protection for anle138b, Matthias stated that initiation of clinical testing would be a cornerstone in boosting the strategic development of the pipeline and would emphasize company’s potential to complement corporate vision and goals.

Dr. Johannes Levin, MODAG’s CMO, said that he envisages anle138b to be a tangible treatment alternative to derail MSA. Highlighting the dearth of disease-stopping treatment alternatives, he went on to add that MSA patients were being a soft target of neurodegenerative diseases, as well as balance, automatic function and progressing movement impairments. Dr. Johannes was optimistic and stated that provided Phase 1 trial would be successful, it would open door for MODAG to examine anle138b in Parkinson and other Parkinson’s disorders.

For the record, as a primary objective, the clinical trial will apparently assess the tolerability and safety of the compound in healthy volunteers. Meanwhile, the secondary objectives incorporate the assessment of the pharmacokinetic profile, along with dose-finding evaluations of both single and multiple ascending doses of anle138b. It is worth noting that anle138b will be managed orally as a single agent to healthy volunteers. Prominently, Recruitment into the trial is afoot and will be undertaken by Quotient Sciences in U.K.
 

Source credit:

https://www.businesswire.com/news/home/20191218005234/en/MODAG-Initiates-First-in-Human-Phase-1-Clinical-Trial

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...